Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN)
Authors:
Open Access
- 17 March 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 164 (2) , 158-169
Abstract
The description of highly exposed individuals who remain seronegative (HESN) despite repeated exposure to human immunodeficiency virus (HIV)‐1 has heightened interest in identifying potential mechanisms of HIV‐1 resistance. HIV‐specific humoral and T cell‐mediated responses have been identified routinely in HESN subjects, although it remains unknown if these responses are a definitive cause of protection or merely a marker for exposure. Approximately half of HESN lack any detectible HIV‐specific adaptive immune responses, suggesting that other mechanisms of protection from HIV‐1 infection also probably exist. In support of the innate immune response as a mechanism of resistance, increased natural killer (NK) cell activity has been correlated with protection from infection in several high‐risk cohorts of HESN subjects, including intravenous drug users, HIV‐1 discordant couples and perinatally exposed infants. Inheritance of protective NK KIR3DL1high and KIR3DS1 receptor alleles have also been observed to be over‐represented in a high‐risk cohort of HESN intravenous drug users and HESN partners of HIV‐1‐infected subjects. Other intrinsic mechanisms of innate immune protection correlated with resistance in HESN subjects include heightened dendritic cell responses and increased secretion of anti‐viral factors such as β‐chemokines, small anti‐viral factors and defensins. This review will highlight the most current evidence in HESN subjects supporting the role of epithelial microenvironment and the innate immune system in sustaining resistance against HIV‐1 infection. We will argue that as a front‐line defence the innate immune response determines the threshold of infectivity that HIV‐1 must overcome to establish a productive infection.Keywords
This publication has 140 references indexed in Scilit:
- BST-2/tetherin: a new component of the innate immune response to enveloped virusesTrends in Microbiology, 2010
- Glycerol monolaurate prevents mucosal SIV transmissionNature, 2009
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008
- The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Journal of Experimental Medicine, 2008
- Differential natural killer cell–mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypesJournal of Experimental Medicine, 2007
- The interferon-induced expression of APOBEC3G in human blood–brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous systemVirology, 2007
- Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1Nature Genetics, 2007
- HIV-1 immunopathogenesis: How good interferon turns badClinical Immunology, 2007
- Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virusJournal of Experimental Medicine, 2006